Form 4: Collegium Pharmaceutical Director Gino Santini Reports Stock Grant

Director Gino Santini reports receiving a grant of restricted stock units (RSUs) from Collegium Pharmaceutical.

Summary

• Gino Santini, a director at Collegium Pharmaceutical, reported a transaction involving the acquisition of 9,791 shares of common stock through restricted stock units (RSUs) on May 15, 2025.
• These RSUs represent a contingent right to receive one share of Collegium Pharmaceutical's common stock each.
• The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon the director's continued service.
• Santini's total holdings following the transaction amount to 85,447 shares.
• The reporting was filed on May 19, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The grant of RSUs is generally viewed positively as it aligns management's interests with shareholders.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The RSUs will be settled on the vesting date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that a director has received stock-based compensation, which is a common practice in publicly traded companies.

Stakeholder Impact

• The grant of RSUs to a director can positively impact shareholders by aligning management's interests with the company's long-term success.

Key Dates

Keywords

Form 4, Director, Gino Santini, Collegium Pharmaceutical, COLL, Restricted Stock Units, RSUs, Beneficial Ownership, Securities